Myfembree for Fibroid-Associated Heavy Menstrual Bleeding
Date: August 9, 2021
Issue #:
1630Summary: Myfembree (Myovant/Pfizer), an oral fixed-dose
combination of the gonadotropin-releasing hormone
(GnRH) receptor antagonist relugolix, the estrogen
estradiol, and the progestin norethindrone acetate,
has been approved by the FDA for management of
heavy menstrual bleeding associated with uterine
leiomyomas (fibroids) in premenopausal women. It is
the second product to be approved in the US for this
indication;Oriahnn, which contains the GnRH receptor
antagonist elagolix in combination with estradiol and
norethindrone acetate, was approved earlier. Relugolix
was approved for treatment of advanced prostate
cancer asOrgovyx in 2020.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Source Type: research
More News: Activella | Bleeding | Cancer | Cancer & Oncology | Cancer of the Uterus | Drugs & Pharmacology | Estradiol | Hormones | Leiomyoma | Men | Oral Cancer | Pfizer | Prostate Cancer | Women